RPESC-RPE-4W
Dry Age-Related Macular Degeneration (AMD) / Geographic Atrophy
Phase 1/2aActive
Key Facts
Indication
Dry Age-Related Macular Degeneration (AMD) / Geographic Atrophy
Phase
Phase 1/2a
Status
Active
Company
About Luxa Biotechnology
Luxa Biotechnology is a private, clinical-stage biotech focused on a first-in-class cell therapy for dry AMD, a leading cause of blindness. The company's core asset, RPESC-RPE-4W, is an adult stem cell-derived retinal pigment epithelial progenitor cell product currently in a Phase 1/2a clinical trial. With a seasoned leadership team featuring stem cell pioneers and experienced biotech executives, Luxa leverages a robust research program and key partnerships with academic and manufacturing centers to advance its therapeutic candidate. The company is pre-revenue and operates as an LLC with headquarters in Cambridge, Massachusetts.
View full company profile